Swiss BC Platforms, which provides genomic data management solutions, has raised $10 million in Series B financing. The round was led by Debiopharm Innovation Fund in conjunction with Tesi, a Finnish venture capital and private equity company, with participation from BC Platforms’ existing investors.

BC Platforms' genomic data management platform enables data integration and secure analysis of molecular and clinical information. The company currently works with over 50 leading international institutions in 19 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies.

"We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round," said Tero Silvola, CEO at BC Platforms. "This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide. Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative."

BC Platforms’ vision is to provide the world’s leading analytics platform for healthcare and industry, with access by 2020 to over 5 million subjects’ diverse genomic and clinical data and samples consolidated from a global network of biobanks - organized repositories of human biological material and associated data stored for research purposes. BC Platforms partners with biobanks to aggregate these data for analysis, and to provide solutions for customers across all therapeutic areas.

Read more: PE Hub (Press release)

Comments are closed.